Sino Biopharmaceutical Reports 2025 Interim Results

Sino Biopharmaceutical Limited (1177.HK) has released its interim results for 2025, indicating a robust growth in the company's profitability. Profit attributable to owners of the parent from continuing operations surged by 140.2% during the reporting period.

The company's sales of innovative products rose 27.2% compared to the previous year, reaching RMB 7.8 billion. Furthermore, Sino Biopharm secured marketing approval for two new innovative products: Putanning (Meloxicam Injection (II)) and Anqixin (Recombinant Human Coagulation Factor VIIa N01 for Injection). The company is actively advancing its drug pipeline, with a total of 37 innovative drug candidates in oncology, 7 related to liver/metabolic diseases, 13 for respiratory diseases, and 6 for surgery/analgesia in clinical trials or regulatory review as of June 2025.

Key developments in drug research include Focus V (Anlotinib Hydrochloride Capsules), a multi-target tyrosine kinase inhibitor. It already has nine approved indications, with three more currently under marketing application review. Additionally, several new indications are progressing through Phase III clinical studies, and the company plans to submit marketing applications for these in the near future.

Between 2023 and 2024, five new innovative oncology drugs and four biosimilars were launched and have become significant contributors to the company's revenue growth in early 2025. The drug Lanifibranor, intended for metabolic dysfunction-associated steatohepatitis (MASH), is also advancing through global Phase III clinical trials. The company continues to invest in research and development and aims for international expansion to drive its innovations.